MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

20.88 -2.02

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.85

Максимум

21.25

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+82.84% upside

Дивиденти
By Dow Jones
Следващи печалби	2.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	628M 1.8B
Предишно отваряне	22.9
Предишно затваряне	20.88

Настроения в новините

By Acuity

40%

60%

150 / 370 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.01.2026 г., 22:18 ч. UTC

Пазарно говорене

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

9.01.2026 г., 21:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9.01.2026 г., 20:39 ч. UTC

Пазарно говорене

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9.01.2026 г., 20:38 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9.01.2026 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9.01.2026 г., 20:30 ч. UTC

Пазарно говорене

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9.01.2026 г., 20:15 ч. UTC

Пазарно говорене

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9.01.2026 г., 20:07 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

9.01.2026 г., 20:07 ч. UTC

Пазарно говорене

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9.01.2026 г., 19:58 ч. UTC

Придобивния, сливания и поглъщания

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9.01.2026 г., 19:42 ч. UTC

Пазарно говорене

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9.01.2026 г., 19:38 ч. UTC

Придобивния, сливания и поглъщания

Wolters Kluwer Acquires StandardFusion >WTKWY

9.01.2026 г., 19:31 ч. UTC

Печалби

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9.01.2026 г., 19:28 ч. UTC

Печалби

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9.01.2026 г., 18:30 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9.01.2026 г., 18:23 ч. UTC

Пазарно говорене

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

9.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.01.2026 г., 17:19 ч. UTC

Пазарно говорене

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9.01.2026 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

9.01.2026 г., 17:07 ч. UTC

Пазарно говорене

McDonald's Promotions Appear Successful -- Market Talk

9.01.2026 г., 17:06 ч. UTC

Пазарно говорене

Oil Futures on Track for Weekly Gains -- Market Talk

9.01.2026 г., 17:05 ч. UTC

Печалби

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9.01.2026 г., 16:57 ч. UTC

Пазарно говорене

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9.01.2026 г., 16:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

9.01.2026 г., 16:46 ч. UTC

Пазарно говорене

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

82.84% нагоре

12-месечна прогноза

Среден 39.11 USD 82.84%

Висок 56 USD

Нисък 27 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

150 / 370 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.